Klygefa FDA Approval: Weekly Subcutaneous C5 Inhibition for AChR-Positive gMG
Generalized myasthenia gravis(gMG)is an autoimmune disorder of the neuromuscular junction.Pathogenic antibodies attack acetylcholine receptors and activate the complement cascade,disrupting nerve-to-muscle signaling.Patients experience fluctuating weakness—ptosis,diplopia,dysarthria,dysphagia,limb fatigue—that worsens with activity.Severe cases can develop respiratory failure.
About 85%of gMG patients are AChR antibody-positive.Terminal complement activation,especially C5 cleavage into C5a/C5b and membrane attack complex(C5b-9)deposition,drives junctional injury.
Klygefa(gefurulimab-gaks)is designed around this mechanism:
Format:bispecific nanobody binding both complement C5 and serum albumin;
Mechanism:blocks C5 cleavage,reduces C5b-9 formation at the neuromuscular junction,lowering complement-mediated damage;albumin binding extends half-life;
Dosing:once-weekly subcutaneous injection,self-administered via auto-injector;
Indication:adults with AChR antibody-positive gMG.
The FDA decision rests on the global phase 3 PREVAIL trial(NCT05556096):260 adults randomized 1:1 to Klygefa or placebo for 26 weeks.Primary endpoint was change in MG-ADL(Myasthenia Gravis Activities of Daily Living)score from baseline at week 26.
Klygefa improved MG-ADL by 1.6 points versus placebo(95%CI:-2.4 to-0.8,P<0.0001);
Clinical improvement was observable as early as week 1;
MG-ADL captures speech,chewing,swallowing,breathing,and limb use—lower scores mean better daily function.
Common adverse events included injection-site reactions,back pain,and vomiting,mostly mild to moderate.Because C5 inhibition raises the risk of serious meningococcal infection,Klygefa carries a boxed warning:patients must complete meningococcal vaccination per the risk-management program before starting therapy,and any signs of infection require urgent evaluation.
For AChR-positive gMG needing durable control,Klygefa combines precise complement suppression with home-based weekly dosing—reducing infusion-center dependency while keeping a validated target engaged.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)